Prospective, multi-center, randomized, open label, active controlled, seamless phase 2/phase3 clinical study to evaluate immunogenicity, safety and tolerability of RelCoVax® (Protein Subunit Vaccine of Reliance Life Sciences Pvt Ltd. against SARS-CoV-2 Virus) and Corbevax® (Protein Subunit Vaccine of Biological E Ltd. against SARS-CoV-2 Virus) administered as primary vaccination.

计划入组 1,550 人

Indicators Affecting PVT Recanalization

计划入组 1,500 人 · 首次发布于 2026 年 3 月 16 日

Study on Yellow Fever Vaccine developed by Serum Institute of India Pvt. Ltd. for comparison of safety and immunogenicity with other vaccine (STAMARIL) In Healthy Infants

计划入组 2,216 人

Adalimumab biosimilar(Reliance Life Sciences Pvt Ltd.)

Filgrastim biosimilar(Reliance Life Sciences Pvt Ltd.)

Ranibizumab biosimilar(Reliance Life Sciences Pvt Ltd.)

Reliance Life Sciences Pvt Ltd.

India

Synergia Life Sciences Pvt Ltd.

India

Suven Life Sciences Ltd.

India

Indian Scientists Develop Revolutionary Liver Support System for Acute Liver Failure Treatment

BIOQuébec and Life Sciences British Columbia Form Strategic Alliance to Strengthen Canada's Life Sciences Ecosystem

Paddington Life Sciences to Lead London-Wide Life Sciences Talent Hub Backed by £3.2 Million Mayoral Investment